Soleno Therapeutics Faces Class Action Over Alleged PWS Drug Safety Misstatements

Soleno Therapeutics, Inc. ($SLNO) is now the subject of a class action lawsuit alleging the company made false and misleading statements regarding its lead drug candidate DCCR, which is being developed to treat Prader-Willi syndrome (PWS). The lawsuit, announced by law firm Bragar Eagel & Squire, P.C., claims the biopharmaceutical company concealed critical safety concerns uncovered during clinical trials and misrepresented the drug's commercial viability to investors. Shareholders who purchased $SLNO shares during the period from March 26, 2025 through November 4, 2025 may be eligible to participate in the legal action.

Key Details of the Alleged Misconduct

According to the complaint, Soleno Therapeutics downplayed evidence of fluid retention issues that emerged during clinical trials of the DCCR drug candidate. The lawsuit alleges that company leadership failed to adequately disclose these safety concerns to investors, instead presenting a more optimistic picture of the drug's safety profile and market potential.

The core allegations center on:

• Undisclosed safety data: The company allegedly concealed or minimized evidence of fluid retention side effects documented in clinical trial data
• Misrepresented commercial viability: Statements about the drug's commercial prospects allegedly did not account for the severity and prevalence of the safety concerns
• Investor harm: The stock price decline following the revelation of these issues harmed investors who purchased shares during the class period

The class action period extends approximately seven and a half months, suggesting that the alleged misconduct persisted through multiple disclosure cycles and investor communications. Prader-Willi syndrome is a rare genetic disorder characterized by severe obesity, intellectual disabilities, and behavioral challenges, making it an area of significant unmet medical need and potential commercial opportunity for any successful therapeutic.

Market Context and Competitive Landscape

The lawsuit arrives during a particularly challenging period for rare disease biotech firms focused on metabolic and genetic disorders. Soleno Therapeutics operates in the ultra-specialized PWS market, where successful drug approvals could command premium pricing due to the condition's severity and limited treatment options.

The DCCR program represents a critical asset for Soleno, as the company's pipeline and commercial prospects are heavily dependent on this single candidate's success. Safety concerns—particularly those involving fluid retention—could be especially problematic for a PWS treatment, given that many patients with this condition already face metabolic and cardiovascular complications.

Key market considerations include:

• Regulatory scrutiny: The FDA has become increasingly focused on cardiovascular and metabolic safety signals in obesity and metabolic disorder treatments
• Investor confidence: Rare disease biotech companies rely heavily on investor sentiment, as clinical-stage programs often have limited near-term revenue prospects
• Competitive dynamics: Other companies developing PWS treatments may benefit from negative sentiment toward $SLNO
• Precedent concerns: Safety-related class actions in biotech often result in substantial settlements, creating financial risk beyond legal fees

Investor Implications and Stock Impact

For Soleno Therapeutics shareholders, this lawsuit creates several layers of financial risk and uncertainty. First, there is direct legal liability—class action settlements in the biotech sector routinely range from millions to tens of millions of dollars, depending on stock price impact and class size. Beyond the settlement itself, ongoing litigation typically dampens investor appetite for the stock and increases volatility.

Second, and perhaps more critically, the lawsuit reinforces questions about the DCCR program's viability. If safety concerns were indeed downplayed, this raises fundamental questions about:

• The likelihood of FDA approval given potential cardiovascular or metabolic complications
• The drug's eventual commercial potential even if approved, given potential safety labeling restrictions
• Management credibility in future investor communications
• Whether SLNO has adequate resources to fund development while managing legal exposure

Investors who purchased shares during the class period may recover losses through the settlement process, but shareholders holding stock beyond the class period face ongoing uncertainty. The stock's performance will likely hinge on how the litigation proceeds and whether Soleno can provide additional clinical or preclinical data to address the safety allegations.

For the broader biotech sector, particularly rare disease and obesity-related therapeutic companies, this lawsuit reinforces the critical importance of robust safety monitoring and complete, timely disclosure of trial results. Regulatory agencies and institutional investors have become exceptionally sensitive to safety signal concealment following high-profile settlements in recent years.

Forward-Looking Outlook

The path forward for Soleno Therapeutics remains highly uncertain. The company faces immediate challenges in defending against the class action while simultaneously navigating regulatory pathways for DCCR. Any adverse regulatory feedback or additional safety signals could substantially accelerate settlement pressure and widen financial exposure.

Investors considering $SLNO positions should carefully monitor:

• Litigation developments: Court filings and settlement negotiations
• Clinical trial updates: Any new safety or efficacy data related to DCCR
• FDA communications: Potential regulatory agency guidance on the safety concerns
• Cash runway: Whether the company has sufficient capital to support both development and litigation costs

The lawsuit fundamentally undermines the bull case for Soleno Therapeutics until resolved, creating a high-risk environment for equity investors. Only new positive clinical data, regulatory clarity, or favorable litigation developments could restore investor confidence in this $SLNO story.